Literature DB >> 12849427

Paraneoplastic neurological syndromes: an update on diagnosis, pathogenesis, and therapy.

Raymond Voltz1.   

Abstract

Since the discovery of the first clinically relevant anti neuronal antibody specific for a paraneoplastic aetiology in 1985, the number of such reactivities has grown at a rate of about one per year. Clinicians can now diagnose a paraneoplastic syndrome much more easily. This ability is especially important because, typically, the neurological symptoms occur before the cancer is diagnosed. Early tumour diagnosis is essential, because effective treatment of the cancer still seems to be the most efficient treatment option for the neurological symptoms. Immuno modulatory therapy should, nevertheless, be initiated as early as possible and seems especially helpful for peripheral syndromes and limbic encephalitis. The recent fundamental advances in understanding of the autoimmune pathology of these disorders, especially the role of cytotoxic T cells, should eventually lead to more effective treatment options.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12849427     DOI: 10.1016/s1474-4422(02)00135-7

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  56 in total

Review 1.  [Use of i.v. immunoglobulins in neurology. Evidence-based consensus].

Authors:  M Stangel; R Gold
Journal:  Nervenarzt       Date:  2004-08       Impact factor: 1.214

Review 2.  Autoimmune stiff person syndrome and related myelopathies: understanding of electrophysiological and immunological processes.

Authors:  Goran Rakocevic; Mary Kay Floeter
Journal:  Muscle Nerve       Date:  2012-05       Impact factor: 3.217

Review 3.  MicroRNA and AU-rich element regulation of prostaglandin synthesis.

Authors:  Ashleigh E Moore; Lisa E Young; Dan A Dixon
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

4.  Paraneoplastic motor neuropathy and inflammatory myopathy associated with nasopharyngeal carcinoma.

Authors:  K H Chan; S Y Leung; R T F Cheung; S L Ho; W Mak
Journal:  J Neurooncol       Date:  2006-07-19       Impact factor: 4.130

5.  Intravenous immunoglobulins in paraneoplastic brainstem encephalitis with anti-Ri antibodies.

Authors:  Arnaud Fumal; Jerome Jobe; Jean-Louis Pepin; Valerie Delvaux; Jean-Marc Senterre; Sandrine Bonaventure; Alain Maertens de Noordhout
Journal:  J Neurol       Date:  2006-09-27       Impact factor: 4.849

6.  Unusual magnetic resonance imaging and cerebrospinal fluid findings in paraneoplastic cerebellar degeneration: a sequential study.

Authors:  C de Andrés; A Esquivel; J G de Villoria; F Graus; S Sánchez-Ramón
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-04       Impact factor: 10.154

7.  Anti-Ma2 antibodies in B-cell primary CNS lymphoma.

Authors:  Markus Kraemer; Peter Berlit
Journal:  J Neurol       Date:  2007-04-10       Impact factor: 4.849

Review 8.  Neuropsychological symptoms in paraneoplastic disorders.

Authors:  Raymond Voltz
Journal:  J Neurol       Date:  2007-05       Impact factor: 4.849

9.  Prolonged refractory status epilepticus with early and persistent restricted hippocampal signal MRI abnormality.

Authors:  Laurent Chevret; Beatrice Husson; Seraphin Nguefack; Astrid Nehlig; Viviane Bouilleret
Journal:  J Neurol       Date:  2008-01-22       Impact factor: 4.849

Review 10.  Polymyositis/dermatomyositis associated with acute myelocytic leukemia.

Authors:  Jia-Kun Shen; Yong-Min Ding; Wen-Jing Zhou; Jie Jin
Journal:  Rheumatol Int       Date:  2008-06-19       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.